Laws governing compensation in case of adverse side effects for Covaxin and Covishield may differ in accordance with the kind of approvals given, say legal experts.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
Face NPPA fine for overcharging on anti-asthma drug
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
Entering Iran may lead to trouble for those having significant presence in the US market.
While several export-oriented Indian companies such as Cipla and Reliance Industries Ltd (RIL) are rejoicing at the prospects of the rupee falling further, others that are importing raw materials such as coal and oil might see a big hole in their bottom line.
Companies run till now by mostly their promoters are increasingly inducting professionals to head their teams.
Yusuf Hamied, Anji Reddy and Parvinder Singh are the real pioneers of the Indian pharmaceutical industry.
A probe finds several pharma majors in breach of the law; and in turn they blame the government.
Regulator says fee would enable it to quicken approval process.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
As the death toll in the country from coronavirus jumped by a record 445 to 13,699, the Centre maintained that the number of infections per lakh population was among the lowest in the world. The new cases surged by over 10,000 for the 11th day in a row and rose by 14,821 to take the total to 4,25,282, according to health ministry data.
To some -- especially western drug companies -- he is a 'pirate'. To others, mostly those in developing countries, he is an unparalleled hero. Either way, Yusuf Hamied, 75, is perhaps the most talked about man in pharmaceutical circles in the last decade.
This move could cost $299 million a year for Indian pharma players.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
Investment banking star and Moelis India Chief Executive Officer Manisha Girotra remembers a colleague who wanted to resign because she needed to attend to her parents' health issues in a different state. Rather than quit a promising career, she was given the flexibility of working from home on Fridays, which was unusual in the pre-pandemic days. This allowed her to take care of her parents' visits to the doctor and other health-related needs without quitting her job. She would be back in the city office on Mondays.
Top officers across various ministries participate in the meeting that started at 8 pm on Saturday. The meeting is currently underway. The country is currently witnessing a second and more severe wave of the pandemic.
Indian auto and pharma industries import several critical components and raw materials from China.
European countries are trying to woo back the Indian customers they had lost following seizure of drug consignments by Customs authorities of several European Union members.
Sun Pharma stock has appreciated at 35% a year for 20 years
Ajit Mishra, vice president, Research, Religare Broking, answers readers' queries on stocks they own or want to buy.
The National Pharmaceutical Pricing Authority, which regulates the prices of medicines, has identified around 70 anti-cancer drugs, including anti-breast cancer medication Letrozole and anti-blood cancer drug Imatinib, for detailed price analysis.
Aggressive smaller players are serving a bitter pill to the big boys in the pharmaceutical sector.
Over 550,000 small drug retailers in the country are transforming into producers and marketers of pharmaceutical products, readying to compete with companies such as Ranbaxy, Cipla, Sun Pharma and Lupin whose produce they sell.
The rupee's appreciation of 6.4 per cent against the dollar and 12 per cent against the euro is likely to hurt the first-quarter performance of the pharmaceutical sector, indicate a results' preview by broking houses.
Ajit Mishra, Vice President, Research, Religare Broking, answers readers' queries on a weekly basis.
The health ministry on Saturday recommended the use of antiviral drug remdesivir in moderate stage of COVID-19 while backtracking from its earlier stance on hydroxychloroquine, saying the anti-malarial drug should be used in the early course of the disease and not on critically ill patients.
Pharmaceutical patents are just over a fourth of all patents granted in the country, but domestic drug makers account for almost all post-grant patent opposition filed, official data reveals.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
As many as 14 Indian families have made it to the inaugural list of Forbes' 50 richest families in Asia.
'Even if Serum Institute and Bharat Biotech were successful in ramping up production overnight, what happens to the capacity after the demand from India is met?' asks Sanjeev Nayyar.
Indian drug companies have cornered an overwhelming majority of drug approvals under the US President's Emergency Plan for AIDS Relief.
Impact of the slowdown is most visible among promoter/owner-CEOs
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
As record stock market rally continues, the value of shares directly owned by next-generation business leaders at 20 major corporate houses has soared over 18 per cent to Rs 17,000 crore.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
An Indian pharmaceutical company is gearing up to sell a cheap version of the leading patented antiviral flu drug Tamiflu to emerging economies, in a move that will pitch intellectual property rights against affordable access to medicines.
